New antibody BEAM-103 enters first human safety trial

NCT ID NCT07304791

Recruiting now Knowledge-focused Sponsor: Beam Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called BEAM-103, a monoclonal antibody, in 30 healthy adults aged 18 to 55. Participants receive a single intravenous dose of either BEAM-103 or a placebo and are monitored for up to 4 months. The main goal is to check the drug's safety and how the body processes it, which will help guide future studies in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BEAM-103 (a monoclonal antibody)
What this could lead to: If successful, this study could help determine safe doses for future trials in patients with certain blood disorders.
What could go wrong: This is a very early Phase 1 trial in only 30 healthy people. It is designed to test safety, not effectiveness, and the drug may not work in patients or may have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANT STUDY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY PARTICIPANT STUDY HEALTHY SUBJECTS

Contacts and locations

Show contact details

Locations

Clinical Study Site
RECRUITING

London, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.